Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014:2014:572491.
doi: 10.1155/2014/572491. Epub 2014 Apr 29.

Isoprostanes and neuroprostanes as biomarkers of oxidative stress in neurodegenerative diseases

Affiliations
Review

Isoprostanes and neuroprostanes as biomarkers of oxidative stress in neurodegenerative diseases

Elżbieta Miller et al. Oxid Med Cell Longev. 2014.

Abstract

Accumulating data shows that oxidative stress plays a crucial role in neurodegenerative disorders. The literature data indicate that in vivo or postmortem cerebrospinal fluid and brain tissue levels of F2-isoprostanes (F2-IsoPs) especially F4-neuroprotanes (F4-NPs) are significantly increased in some neurodegenerative diseases: multiple sclerosis, Alzheimer's disease, Huntington's disease, and Creutzfeldt-Jakob disease. Central nervous system is the most metabolically active organ of the body characterized by high requirement for oxygen and relatively low antioxidative activity, what makes neurons and glia highly susceptible to destruction by reactive oxygen/nitrogen species and neurodegeneration. The discovery of F2-IsoPs and F4-NPs as markers of lipid peroxidation caused by the free radicals has opened up new areas of investigation regarding the role of oxidative stress in the pathogenesis of human neurodegenerative diseases. This review focuses on the relationship between F2-IsoPs and F4-NPs as biomarkers of oxidative stress and neurodegenerative diseases. We summarize the knowledge of these novel biomarkers of oxidative stress and the advantages of monitoring their formation to better define the involvement of oxidative stress in neurological diseases.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Enciu AM, Gherghiceanu M, Popescu BO. Triggers and effectors of oxidative stress at blood-brain barrier level: relevance for brain ageing and neurodegeneration. Oxidative Medicine and Cellular Longevity. 2013;2013:12 pages.297512 - PMC - PubMed
    1. Niki E. Lipid peroxidation products as oxidative stress biomarkers. BioFactors. 2008;34(2):171–180. - PubMed
    1. Santos R, Almodovar CR, Bulteau AL, Gomes CM. Neurodegeneration, neurogenesis, and oxidative stress. Oxidative Medicine and Cellular Longevity. 2013;2013:2 pages.730581 - PMC - PubMed
    1. Cappellano G, Carecchio M, Fleetwood T, et al. Immunity and inflammation in neurodegenerative diseases. American Journal of Neurodegenerative Disease. 2013;2(2):89–107. - PMC - PubMed
    1. Almer G, Teismann P, Stevic Z, et al. Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology. 2002;58(8):1277–1279. - PubMed

MeSH terms

LinkOut - more resources